Orexigenic Therapy With Delta-9-Tetrahydrocannabinol in Advanced Cancer Patients With Chemosensory Abnormalities - a Pilot Study - Related Studies

Orexigenic Therapy With Delta-9-Tetrahydrocannabinol in Advanced Cancer Patients With Chemosensory Abnormalities - a Pilot Study

This study is currently recruiting participants.

Study NCT00316563. Last updated on September 22, 2008. Information provided by Alberta Cancer Board

Find Related Studies by Searching for the Conditions, Interventions, and Sponsors found in this study:


1	Conditions listed in this trial
		Cancer
		Anorexia
		Taste Disorders
		Olfactory Disorders

2	Additional conditions recognized in this trial
		Disease

3	More general conditions related to this trial
		Nervous System Diseases
		Neurologic Manifestations
		Pathologic Processes
		Sensation Disorders
		Signs and Symptoms
		Signs and Symptoms, Digestive

4	Interventions listed in this trial
		Marinol (Dronabinol)
		Placebo

5	Additional drug interventions recognized in this trial
		Tetrahydrocannabinol

6	More general drug interventions related to this trial
		Analgesics
		Analgesics, Non-Narcotic
		Central Nervous System Agents
		Hallucinogens
		Peripheral Nervous System Agents
		Pharmacologic Actions
		Physiological Effects of Drugs
		Psychotropic Drugs
		Sensory System Agents
		Therapeutic Uses

7	Sponsors listed in this trial
		Alberta Cancer Board